(Reuters) -- Swiss-based Roche Holding AG said on Tuesday that talks on settling civil lawsuits arising from a U.S. vitamins price-fixing case were making good progress but it would not confirm a tentative accord had been struck.This content was published on September 7, 1999 - 15:21
(Reuters) -- Swiss-based Roche Holding AG said on Tuesday that talks on settling civil lawsuits arising from a U.S. vitamins price-fixing case were making good progress but it would not confirm a tentative accord had been struck.
"The settlement discussions are well advanced. We are hopeful of making a settlement," a company spokesman said. But he would not confirm a Washington Post report that six big companies had agreed to pay more tha $1.1 billion to settle the lawsuits.
"I cannot confirm the timelines or the amounts mentioned in there," he said. The newspaper had reported the deal would be presented to a U.S. federal judge in about two weeks.
According to the Post, nearly 1,000 corporate buyers of bulk vitamins would get just over $1 billion and some 50 law firms involved in the matter would be paid close to $125 million.
The spokesman for Basle-based Roche noted that Roche had taken a charge of $640 million in the first half to cover exposure to the class-action lawsuits.
This was over and above the $500 million fine Roche paid to settle U.S. criminal charges that it had conspired to fix vitamin prices.
The other companies involved are BASF AG, Rhone-Poulenc SA, Eisai Co, Daichi Pharmaceutical Co and Takeda Chemical Industries Ltd.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: email@example.com